Table 2 Anthropometric and clinical characteristics
Anthropometric characteristics | Intervention (n = 120) | Control (n = 50) | p value | Ambassadors (n = 62) | Healthy age- and sex-matched children (n = 255) |
|---|---|---|---|---|---|
Sex (males/females) | 75/45 (62.5%/37.5%) | 31/23 (57%/43%) | 0.61 | 37/25 (60%/40%) | 180/75 (71%/29%) |
Age (years) | 11.2 ± 3.1 | 11.0 ± 3.2 | 0.44 | 11.9 ± 2.5 | 12.9 ± 3.1 |
Height (m) | 1.52 ± 0.19 | 1.50 ± 0.2 | 0.69 | 1.57 ± 0.16 | 1.58 ± 0.19 |
Weight (kg) | 44.8 ± 17.2 | 41.0 ± 14.0 | 0.21 | 48.4 ± 16.2 | 49.4 ± 16.9 |
BMI (kg/m2) | 18.5 ± 4.0 | 17.6 ± 2.5 | 0.10 | 19.0 ± 3.6 | 17.9 ± 5.2 |
Diagnosis | |||||
Leukemia | 47 (39%) | 23 (46%) | |||
Lymphoma | 22 (18%) | 8 (16%) | |||
Extracranial solid tumors | 35 (29%) | 14 (28%) | |||
Central nervous system tumor | 11 (9%) | 5 (10%) | |||
Other hematological disease | 5 (4%) | 0 (0%) | 0.61 | ||
Treatment protocols | |||||
NOPHO ALL 2008 | 34 | 20 | |||
NOPHO-DBH-AML 2012 | 11 | 3 | |||
ICC APL 01 | 2 | 0 | |||
Euro-LB-02 | 4 | 0 | |||
Euro NET PHL-C1 interrim | 6 | 0 | |||
Euro NET PHL-C2 | 2 | 4 | |||
BFM NHL 2004 | 7 | 0 | |||
BFM NHL 2013 | 3 | 4 | |||
Euro-Ewing 99 | 11 | 2 | |||
EURAMOS-1 | 6 | 4 | |||
CCLG interim | 1 | 0 | |||
EpSSG RMS 2005 | 7 | 4 | |||
EpSSG-NRSTS 2005 | 5 | 0 | |||
UKSSG | 0 | 1 | |||
SIOPEL 6- SR | 1 | 0 | |||
SIOPEL. high risk-PLADO | 1 | 0 | |||
Neoadjuvant (docetaxel/cisplatin/fluorouracil) | 1 | 0 | |||
SIOP-CNS GCT 2 | 3 | 2 | |||
SIOP ependynoma 2 | 2 | 0 | |||
(EU-RHAB) 2009 | 1 | 1 | |||
Angiocomb | 0 | 1 | |||
Herby study | 0 | 2 | |||
SIOP PNET 5 | 3 | 1 | |||
SIOP- LGG 2004 | 1 | 1 | |||
LCH-III | 1 | 0 | |||
Allogeneic transplantation | 4 | 0 | |||
Other | 1 | 0 | |||
No chemotherapy | 2 | 0 | |||
Treatment modalities | |||||
Chemotherapy | 118 | 50 | |||
Radiation therapy | 25 | 10 | |||
Surgery | 40 | 18 | |||
Tumor location | |||||
Central nervous system | 11 | 5 | |||
Head | 6 | 3 | |||
Torso | 13 | 6 | |||
Upper extremity | 3 | 0 | |||
Lower extremity | 13 | 5 | |||